Tovinontrine
As of the edition of 20 October 2026, Tovinontrine is a small molecule: stopped in 2023; acts on PDE9A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 8, 3 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Tovinontrine.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE9A | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | O76083 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 7 | 3 | 1 | 3 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cardurion Pharmaceuticals | Lead sponsor of trials | 2016 to now |
| Enliven Therapeutics | Lead sponsor of trials | 2019 to now |